PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin

Post-Traumatic Stress Disorder (PTSD) is a debilitating condition affecting individuals and society. This review highlights psilocybin's potential as a treatment, noting that after metabolism to psilocin it binds to serotonergic receptors, reducing negative mood, increasing optimism, enhancing introspection, and lowering amygdala reactivity. Animal studies show fear extinction and increased hippocampal neurogenesis. Side effects include nausea and physical discomfort. The review indicates an urgent need for innovative therapies and suggests psilocybin and other psychedelics offer prospects for treating PTSD symptoms directly or as an adjunct to psychotherapy.

Study at a glance

Abstract

Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition that can occur after experiencing or witnessing a traumatic event. The impact of PTSD extends beyond the individual, affecting families, communities, and society as a whole. This study aims to investigate the potential of psilocybin as a treatment for PTSD. Psilocybin, after being metabolized to psilocin, binds to various serotonergic receptors to exert some major effects such as a reduction in negative mood and an increase in optimism, enhanced ability for introspection and perceptual changes, a reduction in amygdala reactivity during emotion processing, and—as has been found in animal studies—an extinction of the fear response and increased hippocampal neurogenesis. However, psychedelics such as psilocybin may lead to brief episodes of nausea, vomiting, and physical discomfort. This study indicated that there is an urgent need for innovative therapies that could enhance the effectiveness of PTSD treatments. As this review highlights, psilocybin and some other psychedelics offer prospects for an additional method of treating PTSD. They have the potential to directly address PTSD symptoms and can also be used as an adjunct to psychotherapy.